Dataset Information

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

ABSTRACT: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2-related cancers. A test to identify additional HRR-deficient tumors will help to extend their use in new indications. We evaluated the activity of the PARPi olaparib in patient-derived tumor xenografts (PDXs) from breast cancer (BC) patients and investigated mechanisms of sensitivity through exome sequencing, BRCA1 promoter methylation analysis, and immunostaining of HRR proteins, including RAD51 nuclear foci. In an independent BC PDX panel, the predictive capacity of the RAD51 score and the homologous recombination deficiency (HRD) score were compared. To examine the clinical feasibility of the RAD51 assay, we scored archival breast tumor samples, including PALB2-related hereditary cancers. The RAD51 score was highly discriminative of PARPi sensitivity versus PARPi resistance in BC PDXs and outperformed the genomic test. In clinical samples, all PALB2-related tumors were classified as HRR-deficient by the RAD51 score. The functional biomarker RAD51 enables the identification of PARPi-sensitive BC and broadens the population who may benefit from this therapy beyond BRCA1/2-related cancers.

SUBMITTER: Castroviejo-Bermejo M

PROVIDER: S-EPMC6284440 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo Marta M Cruz Cristina C Llop-Guevara Alba A Gutiérrez-Enríquez Sara S Ducy Mandy M Ibrahim Yasir Hussein YH Gris-Oliver Albert A Pellegrino Benedetta B Bruna Alejandra A Guzmán Marta M Rodríguez Olga O Grueso Judit J Bonache Sandra S Moles-Fernández Alejandro A Villacampa Guillermo G Viaplana Cristina C Gómez Patricia P Vidal Maria M Peg Vicente V Serres-Créixams Xavier X Dellaire Graham G Simard Jacques J Nuciforo Paolo P Rubio Isabel T IT Dienstmann Rodrigo R Barrett J Carl JC Caldas Carlos C Baselga José J Saura Cristina C Cortés Javier J Déas Olivier O Jonkers Jos J Masson Jean-Yves JY Cairo Stefano S Judde Jean-Gabriel JG O'Connor Mark J MJ Díez Orland O Balmaña Judith J Serra Violeta V

EMBO molecular medicine 20181201 12

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2-related cancers. A test to identify additional HRR-deficient tumors will help to extend their use in new indications. We evaluated the activity of the PARPi olaparib in patient-derived tumor xenografts (PDXs) from breast cancer (BC) patients and investigated mechanisms of sensitivity through exome sequencing, <i>BRCA1</i> promoter methylation ...[more]

PMID: 30377213

Similar Datasets

Project description:Background:BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. Patients and methods:We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. Results:RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1-loss in 20% and RAD51-amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Conclusion:Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.

Dataset Information

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Publications

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets